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Dear Sir,  
Rau and colleagues described the impact of genetic polymorphisms in SLC28 genes encoding for 
concentrative nucleoside transporter 2 (CNT2) and 3 (CNT3) and inosine triphosphatase (ITPA) 
variants on ribavirin (RBV) serum levels, hemoglobin drop and therapeutic response in patients 
with HCV infection [1]. In this paper they cited our observation that single nucleotide polymorphism 
(SNP) in the SLC28A2 encoding region (rs11854484) was an independent predictor of sustained 
virological response (SVR) [2, 3]. Our hypothesis was that this effect could be explained by the 
different ability of CNT2 forms to internalize RBV within cells, and not with a direct effect on RBV 
plasma levels.  
In the era of dual PEG-interferon (PEG-IFN)/RBV therapy, most of the studies that investigated the 
role of RBV pharmacokinetics (Pk) found a clear association between higher RBV exposure and a 
higher chance of both SVR and anaemia, as expected on the basis of the recognized 
proportionality between RBV daily dose and these two outcomes [4]. Even in most recent studies, 
where patients were stratified according to human genetic polymorphisms, RBV Pk retained its 
significant role in predicting both efficacy and toxicity in PEGIFN/RBV intakers [2, 3, 5-7]. While the 
need for RBV as part of new triple therapies has been proven in development trials [8], it remains 
to be determined whether RBV Pk has still any impact on treatment outcomes with highly effective 
direct acting antivirals (DAAs). Then, the ability to early predict with genetics or therapeutic drug 
monitoring (TDM) ribavirin plasma concentrations at steady state retains its clinical importance. 
Rau and colleagues described the association between CNT2 SNPs and RBV plasma 
concentrations. It should be noted that these PK/PG analyses were conducted on 67 patients only, 
without dose correction verification, including patient with modified dosage. In addition, they only 
reported a trend for statistical significance for the association of RBV concentration and SLC28 
genotypes [1]. Our observations did not support this association [2, 3]: CNT2 SNPs were not 
associated with plasma RBV concentrations (after 4 weeks) while adjusting for the dose pro 
kilogram and for dose reduction, and only using several SNPs [rs11854484, rs2413775 and 
rs1060896] in “unfavorable” (for lower ribavirin concentrations) combinations (on 186 HCV+ 
patients) it was possible to demonstrate a statistical significance (p=0.009) [Figure 1]. On the 
contrary week 4 RBV plasma exposure seems to be nicely predicted by week 2 concentrations 
suggesting a possible early use of TDM to adjust the drug exposure both to enhance efficacy and 
reduce toxicity (p <0.001) [9, 10]. 
We therefore have no clear answer to the question whether genetic SLC28 transporter 
polymorphisms predict ribavirin plasma levels. If RBV plasma exposure maintains its clinical 
impact in new anti-HCV treatment studies comparative evaluations of pharmacogenetics vs. early 
pharmacokinetics are warranted. It should also be highlighted that the cost of a single early (2 
weeks) determination of ribavirin plasma concentration does not significantly impact on the overall 
expenditure associated to the use of (triple) anti-HCV therapy and may well contribute to a fruitful 
tailored management.  
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Figure 1. Lower plasma concentrations of ribavirin were related with higher number of 
"unfavorable" CNT2 SNPs (rs11854484 [TT], rs2413775 [AT/TT] and rs1060896 [CC]). Only the 
difference between the group "0" and "3" is statistically significant (p=0.006). 
 
